Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Cisplatin 85pembrolizumab 76Magnetic Resonance Spectroscopy 46Radiotherapy, Intensity-Modulated 41Specimen Handling 36Cetuximab 36Carboplatin 35Radiotherapy 34Nivolumab 28Paclitaxel 24Radiation 22Platinum 22Docetaxel 20Biopsy 201,2-diaminocyclohexaneplatinum II citrate 20Gemcitabine 19Surveys and Questionnaires 15Fluorouracil 14toripalimab 13Standard of Care 12Taxes 11cemiplimab 9atezolizumab 9Ipilimumab 9Drug Therapy 9Cyclophosphamide 9X-Rays 8Surgical Procedures, Operative 8Radiosurgery 7Immunoglobulin G 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Patient Reported Outcome Measures × Head & Neck × 90 days × Clear all
NCT04146064 2026-05-08

Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response

University Health Network, Toronto

Completed
190 enrolled
DermatologicGenitourinaryHead & Neck

Carcinoma, Transitional Cell, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡